Uniphar (UPR.IR) Azione Prezzo
Uniphar Prezzo
Negli ultimi 13 anni Uniphar ha aumentato il fatturato del 12,8% all'anno, raggiungendo 3,07 miliardi EUR. L'utile per azione è cresciuto del 24,4% all'anno negli ultimi 10 anni. Per Uniphar, il margine netto del 1,7% risulta sostanzialmente stabile rispetto al 2,5% di alcuni anni fa. Al prezzo attuale il rendimento da dividendo è pari a circa il 0,45%. Il payout ratio è pari a circa il 10% degli utili. Il dividendo è cresciuto del 21,8% all'anno negli ultimi 5 anni. Il target di prezzo di consenso a 12 mesi per Uniphar è 4,94 EUR, circa il 13,1% sopra il prezzo attuale di mercato. Su 12 analisti, 11 valutano il titolo come acquisto — nel complesso un consenso Acquistare.
Uniphar Prezzo delle azioni
Accedi a questi dati tramite l’API Eulerpool
100.000 richieste/mese gratis · nessuna carta di credito
Uniphar Azione e analisi azionaria
Domande frequenti sull'azione Uniphar
The business model of Uniphar PLC revolves around being a diversified healthcare services provider. Uniphar operates across three divisions, including Commercial & Clinical, Supply Chain & Retail, and Product Access. The Commercial & Clinical division focuses on providing support services to pharmaceutical manufacturers, while the Supply Chain & Retail division specializes in the distribution and retail of pharmaceutical and healthcare products. Lastly, the Product Access division concentrates on the sourcing and distribution of specialty pharmaceuticals. Uniphar PLC aims to deliver innovative and sustainable solutions to the healthcare industry, while offering a wide range of services and products to meet the evolving needs of their customers.
Uniphar PLC is primarily active in the healthcare and pharmaceutical industries.
The main competitors of Uniphar PLC in the market include companies like McKesson, AmerisourceBergen, and Cardinal Health. These companies operate in the same industry as Uniphar, providing pharmaceutical and healthcare distribution services. Other competitors that Uniphar faces in specific segments of its business include Sisk Healthcare, United Drug, and DCC Healthcare. Uniphar PLC competes with these industry players to gain market share and maintain its position in the healthcare and pharmaceutical distribution sector.
Uniphar PLC is a leading healthcare services provider based in Ireland. Established in 1967, the company has a rich history of over 50 years. Initially a wholesale pharmaceutical business, Uniphar expanded its operations to include integrated commercial and clinical services. Today, it offers a comprehensive range of services to the healthcare industry, including supply chain management, retail pharmacy, product licensing, and support services. Uniphar has a strong presence in Ireland and the UK, and its diverse customer base includes hospitals, pharmacies, pharmaceutical manufacturers, and the government. The company's commitment to innovation, reliability, and customer satisfaction has propelled it to become a trusted partner in the healthcare sector.
Some significant milestones achieved by Uniphar PLC include its successful listing on the Euronext Dublin and London Stock Exchanges in July 2019, marking a significant step in its growth and expansion plans. The company has also made strategic acquisitions, such as the acquisition of M3 Medical Limited in 2020, which strengthened its position in the Irish healthcare market. Furthermore, Uniphar PLC has consistently delivered strong financial performance, with revenue and profit growth year after year. Its focus on innovation and developing new capabilities has allowed the company to enhance its offering and provide comprehensive solutions to the healthcare industry.
Uniphar PLC is primarily present in Ireland, the United Kingdom, and the Benelux region. This pharmaceutical and healthcare services company operates across these countries, providing a wide range of services to healthcare providers, manufacturers, and patients. Uniphar PLC's strong presence in these regions allows them to leverage their expertise and network for the benefit of their customers.
Uniphar PLC represents values of integrity, collaboration, innovation, and customer-focus. With a strong corporate philosophy centered around delivering excellence in healthcare, Uniphar is committed to providing high-quality products and services to improve patient outcomes. The company places great emphasis on building trusted partnerships with healthcare professionals and industry stakeholders, enabling them to navigate complex healthcare supply chains effectively. Uniphar's dedication to continuous innovation and adaptability in a rapidly evolving industry sets it apart. By prioritizing customer needs and maintaining a steadfast focus on ethical practices, Uniphar PLC has established itself as a leading player in the healthcare sector.
Gli analisti fissano attualmente un prezzo obiettivo medio di 4,93 EUR per l’azione Uniphar (mediana: 4,94 EUR), pari a +13,0 % rispetto all’ultimo prezzo. Il consenso si basa su 12 giudizi di analisti.
12 analisti valutano attualmente l’azione Uniphar: 11 raccomandano l’acquisto, 1 la tenuta e 0 la vendita. Per il 2026 gli analisti si aspettano per Uniphar ricavi pari a 3,24 miliardi EUR e un utile per azione di 0,28 EUR.
L’azione Uniphar (UPR.IR) è quotata su 4 borse, tra cui: London (UPR.L), Frankfurt (0NR.F), München (0NR.MU).
Uniphar PLC is a leading provider of healthcare solutions and pharmaceutical products in Europe. The company offers a wide range of services and products that meet the medical needs of patients. Uniphar was founded in 1994 and has been a publicly listed company since 2019. The business model of Uniphar is focused on offering a comprehensive range of services and products in various areas of healthcare. The company has different divisions tailored to the needs of its customers. The division "Uniphar Retail Services" specializes in wholesale and retail. The division offers a wide range of retail products, including over-the-counter medications, dietary supplements, medical devices, and cosmetics. Uniphar also works closely with retailers to develop customized solutions for their needs. Uniphar also has a division called "Uniphar Group" that specializes in providing pharmaceutical products to hospitals and clinics. In addition, the division also offers solutions for drug manufacturing and delivery. Through close collaboration with the pharmaceutical industry, the company also offers solutions for the trade of pharmaceutical products. The division "Uniphar Specialty Healthcare" specializes in the distribution of specialized drugs. The company offers a wide range of medical products for the treatment of chronic conditions such as diabetes, cancer, and HIV/AIDS. The division also works closely with healthcare professionals and hospitals to ensure that patients receive the right medications. Uniphar has also developed a digital platform called "Uniphar Connect". This platform allows customers and business partners to access a wide range of products and services offered by Uniphar. The platform also provides efficient order and delivery processing to ensure that customers receive their required products quickly and easily. Overall, Uniphar has a diversified product portfolio and offers a comprehensive range of services tailored to the needs of the healthcare industry. The company has a strong presence in Europe and works closely with its customers and partners to develop customized solutions for their needs. With a strong focus on digital innovation and strategic partnerships, the company is well positioned to be successful in the future.
Il attesa fatturato di Uniphar ammonta a 3,24 miliardi EUR. Questo dato si basa sui dati finanziari attuali e riflette lo sviluppo commerciale dell'azienda.
Il attesa profitto di Uniphar ammonta a 73,09 Mio. EUR. L'utile netto riflette la redditività dell'azienda dopo la deduzione di tutti i costi.
Il rapporto prezzo/utili (P/E) di Uniphar è attualmente 15,50. Il rapporto P/E confronta il prezzo attuale dell'azione con l'utile per azione e aiuta gli investitori a valutare la valutazione dell'azione Uniphar.
Il rapporto prezzo/fatturato (P/S) di Uniphar è attualmente 0,35. Il rapporto P/S confronta la capitalizzazione di mercato con il fatturato annuo e funge da indicatore di valutazione dell'azione Uniphar.
Il Quality Score AlleAktien per Uniphar è 5/10.
L'ISIN di Uniphar è IE00BJ5FQX74. L'ISIN (International Securities Identification Number) è un codice identificativo univoco a livello mondiale per i titoli.
Il WKN di Uniphar è A2PNWJ. Il WKN (Wertpapierkennnummer) è un codice identificativo tedesco a sei cifre per i titoli.
Il ticker di Uniphar è UPR.IR. Con questo simbolo di borsa vengono negoziate le azioni Uniphar in borsa.
Azione Uniphar
Gruppo di pari di Uniphar
Uniphar Ticker
Uniphar FIGI
Altre metriche e analisi di Uniphar in Deep Dive.
La nostra analisi azionaria dell'azione Uniphar include importanti indicatori finanziari come il fatturato, l'utile, il P/E, il P/S, l'EBIT, oltre a informazioni sul dividendo. Inoltre, esaminiamo aspetti come le azioni, la capitalizzazione di mercato, il debito, il patrimonio netto e le passività di Uniphar. Se state cercando informazioni più dettagliate su questi temi, sulle nostre sottopagine offriamo analisi approfondite: